空间特征揭示PD-1免疫逃逸为富T细胞/组织细胞型大B细胞淋巴瘤的定义性特征
该研究对多机构TCRLBCL队列进行PD-1/PD-L1通路的遗传与定量空间分析,发现64%病例恶性B细胞存在PD-L1/PD-L2拷贝数增加或扩增且与PD-L1表达升高相关(P=.0111)。空间分析显示TCRLBCL以恶性B细胞周围大量PD-L1+巨噬细胞和PD-1+T细胞为特征,可区分cHL和DLBCL-NOS;5例复发/难治患者中3例对PD-1阻断有临床反应。
要点
- TCRLBCL中64%病例恶性B细胞存在PD-L1/PD-L2拷贝数增加或扩增。
- 空间分析显示肿瘤免疫微环境中PD-L1+巨噬细胞和PD-1+T细胞高度富集。
- 5例复发/难治TCRLBCL中3例对PD-1阻断有反应(2例CR,1例PR)。
核心结论
- PD-1信号通路是TCRLBCL的免疫逃逸途径,空间分辨免疫特征有助于诊断分类和免疫治疗优先级判定。
研究设计与样本
- 多机构TCRLBCL队列的遗传与定量空间分析研究。
主要发现
- 64%的TCRLBCL病例恶性B细胞存在PD-L1/PD-L2拷贝数增加或扩增,与PD-L1表达升高相关(P=.0111)。
- TCRLBCL以恶性B细胞被大量PD-L1表达肿瘤相关巨噬细胞和PD-1+T细胞包围的肿瘤免疫邻域为特征。
- 空间分辨免疫特征的无偏聚类可将TCRLBCL与经典型霍奇金淋巴瘤和DLBCL-NOS区分。
- 5例复发/难治TCRLBCL患者接受PD-1阻断治疗,3例有临床反应,包括2例完全缓解和1例部分缓解。
临床怎么用
- PD-1阻断可能对复发/难治TCRLBCL患者具有治疗潜力。
- 空间分辨免疫特征可能辅助TCRLBCL的诊断分类和免疫治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell/histiocyte-rich large B-cell lymphoma (TCRLBCL) is an aggressive variant of diffuse large B-cell lymphoma (DLBCL) characterized by rare malignant B cells within a robust but ineffective immune cell infiltrate. The mechanistic basis of immune escape in TCRLBCL is poorly defined and not targeted therapeutically. We performed a genetic and quantitative spatial analysis of the PD-1/PD-L1 pathway in a multi-institutional cohort of TCRLBCLs and found that malignant B cells harbored PD-L1/PD-L2 copy gain or amplification in 64% of cases, which was associated with increased PD-L1 expression (P = .0111). By directed and unsupervised spatial analyses of multiparametric cell phenotypic data within the tumor microenvironment, we found that TCRLBCL is characterized by tumor-immune "neighborhoods" in which malignant B cells are surrounded by exceptionally high numbers of PD-L1-expressing TAMs and PD-1+ T cells. Furthermore, unbiased clustering of spatially resolved immune signatures distinguished TCRLBCL from related subtypes of B-cell lymphoma, including classic Hodgkin lymphoma (cHL) and DLBCL-NOS. Finally, we observed clinical responses to PD-1 blockade in 3 of 5 patients with relapsed/refractory TCRLBCL who were enrolled in clinical trials for refractory hematologic malignancies (NCT03316573; NCT01953692), including 2 complete responses and 1 partial response. Taken together, these data implicate PD-1 signaling as an immune escape pathway in TCRLBCL and also support the potential utility of spatially resolved immune signatures to aid the diagnostic classification and immunotherapeutic prioritization of diverse tumor types.
引用
- Griffin GK, Weirather JL, Roemer MGM, et al. Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2021. PMID: 32871584. doi:10.1182/blood.2020006464
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。